Charles Goodwin : Yeah, no, it’s a really good question. And remember that worldwide, we grew, we grew generators 20 – we grew our installed base in our active or in the U.S., actually we grew our installed base and our active installed base 20% even through, even through all the things at the safety notice. And outside the United States, it’s a little bit tougher because of our indirect model. But, yeah, I think the – when we were down in Brazil the part that was tough for the Latin American audience to understand was the part of the safety know that’s where it says do not use after lipo. And after talking through that and walking them through that and the customers through that we made a lot of headway there and a lot of understanding on exactly what was going on.
And I think that’s why we saw such a strong fourth quarter in Latin America and we would expect improving trends in a lot of different areas as we move forward this year. And I think that, once we are able to get through of all of this, I think that, yes, that will take care of any existing markets that are out there today.
Matt Hewitt : That’s great. Thank you.
Operator: Our next question is from Frank Takkinen with Lake Street Capital Markets. Please proceed.
Frank Takkinen : Hey, thanks for taking my questions. Wanted to first start with one of the most recent 510(k) clearance. Can you just speak to whether or not that actually, technically does cover use after liposuction? And whether or not there could be a potential amendment to the safety notification that’s out there right now based on that 510(k) in advance of the actual specific, lipo 510(k)?
Charles Goodwin : Yeah. So, I’m not going to answer the second question, obviously, we’re working with the agency and doing everything we can to the agency to make sure that they are comfortable with the safety and the efficacy profile of our technology. And so that remains obviously a huge focus for us. But when you’re talking about the second indication that we just obtained on February 27th, it has the contraction of soft tissue everywhere on the body and as needed. And so the real question is, is it needed after liposuction? And if the answer to that is, yeah, that that 510(k) suffice us for that. And so, it was an important 510(k) for us to get. It obviously shows that the agency believes that the technology is safe and effective. And now, we as an organization are still working through with the agency. And we still have our submission in that we submitted at the end of January.
Frank Takkinen : Okay that’s helpful. And then just for my second one maybe on the cash balance assuming the sale-leaseback closes and including the $8 million from MidCap, that got yet pro forma around the $25 million mark using year-end cash. Is that enough to drop the going concern? Or do you still need the tax credit to and have that going concern drop?
Tara Semb : Well, we expect to end again the year 2023 with $18 million in cash and that’s based on normalized operating investing activities of $14.5 million in 2023. $500,000 of which is CapEx and it also assumes that our non-cash items including depreciation and amortization are offset by cash used in working capital. And we do have the discrete items, the sale-leaseback and the tax refund, as well as the net proceeds of $8 million on our loan. We are not assuming in our guidance, anything on additional borrowings on either of the term, the term loan or the revolver in 2023 as we progress through that and those things do happen the tax refund comes in and we do close on the sale-leaseback that should remove the need to disclose anything.
